Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder.

Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, Chamari M, Djazayery A.

Psychiatry Res. 2010 Jun 30;178(1):112-5. doi: 10.1016/j.psychres.2009.04.013. Epub 2010 May 13.

PMID:
20466437
2.

Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.

Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M.

Aust N Z J Psychiatry. 2008 Mar;42(3):192-8. doi: 10.1080/00048670701827275.

PMID:
18247193
3.

Serum cortisol concentration in patients with major depression after treatment with fluoxetine.

Piwowarska J, Chimiak A, Matsumoto H, Dziklińska A, Radziwoń-Zaleska M, Szelenberger W, Pachecka J.

Psychiatry Res. 2012 Aug 15;198(3):407-11. doi: 10.1016/j.psychres.2012.01.029. Epub 2012 Mar 17.

PMID:
22429479
4.

Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.

Hernández ME, Mendieta D, Martínez-Fong D, Loría F, Moreno J, Estrada I, Bojalil R, Pavón L.

Eur Neuropsychopharmacol. 2008 Dec;18(12):917-24. doi: 10.1016/j.euroneuro.2008.08.001. Epub 2008 Sep 20.

PMID:
18805677
5.

Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment.

Song C, Halbreich U, Han C, Leonard BE, Luo H.

Pharmacopsychiatry. 2009 Sep;42(5):182-8. doi: 10.1055/s-0029-1202263. Epub 2009 Sep 1.

PMID:
19724980
6.

The mothers, Omega-3 and mental health study.

Mozurkewich E, Chilimigras J, Klemens C, Keeton K, Allbaugh L, Hamilton S, Berman D, Vazquez D, Marcus S, Djuric Z, Vahratian A.

BMC Pregnancy Childbirth. 2011 Jun 22;11:46. doi: 10.1186/1471-2393-11-46.

7.

Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder.

Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, Huebinger RM, Barber RC, Trivedi MH.

Mol Psychiatry. 2013 Oct;18(10):1119-24. doi: 10.1038/mp.2012.125. Epub 2012 Aug 28.

8.

Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study.

Ventura-Juncá R, Symon A, López P, Fiedler JL, Rojas G, Heskia C, Lara P, Marín F, Guajardo V, Araya AV, Sasso J, Herrera L.

BMC Psychiatry. 2014 Aug 3;14:220. doi: 10.1186/s12888-014-0220-0.

9.

Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.

Khoraminya N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayery A.

Aust N Z J Psychiatry. 2013 Mar;47(3):271-5. doi: 10.1177/0004867412465022. Epub 2012 Oct 23.

PMID:
23093054
10.

Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial.

Mocking RJ, Assies J, Bot M, Jansen EH, Schene AH, Pouwer F.

PLoS One. 2012;7(11):e49431. doi: 10.1371/journal.pone.0049431. Epub 2012 Nov 28.

11.

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S.

J Affect Disord. 2012 Dec 10;141(2-3):308-14. doi: 10.1016/j.jad.2012.03.033. Epub 2012 Apr 18.

PMID:
22516310
12.

Cytokine profiles in women with different subtypes of major depressive disorder.

Marques-Deak AH, Neto FL, Dominguez WV, Solis AC, Kurcgant D, Sato F, Ross JM, Prado EB.

J Psychiatr Res. 2007 Jan-Feb;41(1-2):152-9. Epub 2005 Dec 20.

PMID:
16375926
13.

Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids.

Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C.

J Psychiatr Res. 2009 Jan;43(4):471-6. doi: 10.1016/j.jpsychires.2008.06.003. Epub 2008 Jul 21.

PMID:
18640689
14.

Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features.

Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D.

Psychiatry Res. 2012 Jun 30;198(1):74-80. doi: 10.1016/j.psychres.2011.12.007. Epub 2012 Mar 3.

PMID:
22386567
15.

Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder.

Keating C, Dawood T, Barton DA, Lambert GW, Tilbrook AJ.

BMC Psychiatry. 2013 Apr 29;13:124. doi: 10.1186/1471-244X-13-124.

16.

Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity.

Kaestner F, Hettich M, Peters M, Sibrowski W, Hetzel G, Ponath G, Arolt V, Cassens U, Rothermundt M.

J Affect Disord. 2005 Aug;87(2-3):305-11.

PMID:
15951024
17.

Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine.

Piwowarska J, Dryll K, Szelenberger W, Pachecka J.

Acta Pol Pharm. 2008 Jan-Feb;65(1):159-64.

18.

Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.

Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR.

Psychopharmacology (Berl). 2001 Jun;156(1):73-8.

PMID:
11465636
19.

Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response.

Mocking RJ, Verburg HF, Westerink AM, Assies J, Vaz FM, Koeter MW, Ruhé HG, Schene AH.

Psychoneuroendocrinology. 2015 Sep;59:1-13. doi: 10.1016/j.psyneuen.2015.04.027. Epub 2015 May 11.

PMID:
26010860
20.

[Lipids, depression and suicide].

Colin A, Reggers J, Castronovo V, Ansseau M.

Encephale. 2003 Jan-Feb;29(1):49-58. Review. French.

PMID:
12640327
Items per page

Supplemental Content

Write to the Help Desk